STOCK TITAN

Natera Inc - NTRA STOCK NEWS

Welcome to our dedicated news page for Natera (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Natera's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Natera's position in the market.

Rhea-AI Summary
Natera, Inc. collaborates with French organizations on a phase III clinical trial for colorectal cancer, evaluating the benefits of adjuvant chemotherapy based on circulating tumor DNA detection. The study aims to impact treatment decisions for stage II CRC patients, potentially setting a new standard of care in France.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
clinical trial
-
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) sees positive implications from the 2024 Clinical Practice Guideline for Chronic Kidney Disease (CKD) by KDIGO. The guideline supports genetic testing for CKD patients, emphasizing its impact on clinical management. Natera's Renasight test aligns with the guideline's recommendations, providing actionable gene categories for CKD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
-
Rhea-AI Summary
Natera, Inc. (NTRA) presents new data on Signatera™ and Empower™ tests at the SGO Annual Meeting, showcasing the predictive and prognostic utility of Signatera in ovarian cancer and other gynecologic malignancies. The company continues to lead in MRD testing, with Medicare coverage expansions indicating growing clinical value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
conferences
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) secures commercial insurance coverage for its Prospera Heart and Prospera Kidney tests from a major Blue Cross Blue Shield plan in the U.S. The tests analyze donor-derived cfDNA to assess organ transplant rejection risk. This move enhances access for commercially insured transplant patients, aligning with recent medical society endorsements. Natera's organ health products have robust peer-reviewed evidence backing their clinical utility, with ongoing trials to further validate Prospera's effectiveness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
none
-
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) will participate in investor conferences in March, including Raymond James 45th Annual Institutional Investors Conference and TD Cowen 44th Annual Health Care Conference. The events will have live webcasts and audio archives accessible through the Natera website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.98%
Tags
conferences
-
Rhea-AI Summary
Natera, Inc. (NTRA) reports strong financial results for Q4 2023, showing significant revenue growth and test volume increases. The company achieved total revenues of $311.1 million in Q4 2023, up 43.2% from the previous year, with product revenues growing by 44.3%. Natera processed approximately 2,496,100 tests in 2023, a 20.8% increase from 2022. The company's gross margins improved to 51.4% in Q4 2023. Natera expects 2024 revenue of $1.32 billion-$1.35 billion and continues to focus on innovation and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.98%
Tags
earnings
Rhea-AI Summary
Natera, Inc. (NTRA) progresses in patent infringement litigation against CareDx with a $96.3 million jury verdict in lost profits and past royalties. The U.S. District Court will decide on future royalties for ongoing AlloSure testing. Discovery and briefing to continue till summer 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
none
-
Rhea-AI Summary
Natera, Inc. (NTRA) announces that its Signatera MRD test has met coverage requirements from CMS in new indications for ovarian and breast cancer. The test has shown promising results in detecting recurrence early and predicting therapy response, potentially improving outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
none
-
Rhea-AI Summary
Natera, Inc. (NTRA) to release Q4 and year-end 2023 financial results on Feb. 28, 2024. Conference call and webcast to follow. Details provided for investors and traders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
earnings
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced a study validating its MRD test, Signatera, in endometrial cancer. The study showed that patients who tested Signatera MRD-positive experienced significantly higher rates of recurrence, making Signatera a powerful post-surgical biomarker of recurrence risk for patients with endometrial cancer. The potential for Signatera to redefine adjuvant treatment pathways in endometrial cancer was demonstrated in the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
Natera Inc

Nasdaq:NTRA

NTRA Rankings

NTRA Stock Data

10.92B
116.37M
4.14%
95.85%
7.08%
Medical Laboratories
Health Care and Social Assistance
Link
United States
Austin

About NTRA

natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the